title: Vioxx, Celebrex, Bextra....do we have a new target for anti-inflammatory and antipyretic therapy?
authors.forename: Andrej A
authors.initials: AA
authors.lastname: Romanovsky
mesh_terms: D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology*; D000068579:Celecoxib; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology*; D015195:Drug Design; D006801:Humans; D019746:Intramolecular Oxidoreductases / Q000037:antagonists & inhibitors*; D007555:Isoxazoles / Q000494:pharmacology; D007783:Lactones / Q000494:pharmacology; D008861:Microsomes / Q000201:enzymology; D000071876:Prostaglandin-E Synthases; D011720:Pyrazoles / Q000494:pharmacology; D013449:Sulfonamides / Q000494:pharmacology; D013450:Sulfones / Q000494:pharmacology; D000096926:Benzenesulfonamides
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000068579:Celecoxib; D016861:Cyclooxygenase Inhibitors; D019746:Intramolecular Oxidoreductases; D007555:Isoxazoles; D007783:Lactones; D000071876:Prostaglandin-E Synthases; D011720:Pyrazoles; D013449:Sulfonamides; D013450:Sulfones; C116926:rofecoxib; C406224:valdecoxib; D000096926:Benzenesulfonamides